Sunil Kumar/LinkedIn
Dec 17, 2025, 23:37
Sunil Kumar: Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024)
Sunil Kumar, Entrepreneur of Medifit Devices LLP, shared a post on LinkedIn:
“Top 10 Drugs Driving Revenue in Rare Disease Therapeutics (2024).
Rare diseases may affect smaller patient populations, but strong science, high unmet need, and long term therapy adoption continue to translate into meaningful revenues. From enzyme replacement therapies to advanced coagulation factors, these products underline the commercial strength of rare disease portfolios.
The list highlights reported 2024 revenues along with primary approved indications across areas such as amyloidosis, hemophilia, and inherited metabolic disorders.”
Stay updated with Hemostasis Today.
-
Jun 11, 2026, 12:58Joseph R. Shaw: Beyond Predictable Pharmacokinetics in DOAC Therapy
-
Jun 11, 2026, 12:40Khechar N Paudel: The Nepal Stroke Project Brings Evidence-Based Stroke Care to Remote Communities
-
Jun 11, 2026, 12:35Sergey Badalyan: EHA2026 Opening Ceremony – The Importance of Building Communities, Not Projects
-
Jun 11, 2026, 12:15Welcome to EHA 2026
-
Jun 11, 2026, 08:35Mohamed Reda: CBC Report – More Than Just Numbers
-
Jun 11, 2026, 07:59Uday Sankar Akash Vankayala: Key Findings on IBD-Associated VTE Phenotypes and Inpatient Burden
-
Jun 11, 2026, 07:41Zia Ullah: Hidden Cerebral Venous Sinus Thrombosis After Dengue Recovery
-
Jun 11, 2026, 07:24Aaron Rodriguez Calienes: RESISTANT Registry Provides Reassuring Safety Data for Acute Intracranial Stenting
-
Jun 11, 2026, 07:17Mbunya. S. Misiani: From the WFH Congress to Meaningful Change for Patients with Bleeding Disorders Worldwide